Revolution Medicines (RVMD) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $37.2B
- As of Nov 13, 2026
- P/E
- -19.90x
- Trailing twelve months
- P/B
- 15.49x
- Latest reported equity
- P/S
- Not available
- Trailing twelve months
- ROE
- -77.9%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $37.2B
- As of Nov 13, 2026
- P/E
- -19.90x
- Trailing twelve months
- P/B
- 15.49x
- Latest reported equity
- P/S
- Not available
- Trailing twelve months
- ROE
- -77.9%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-19.90x
Net loss — not comparable
P/B
15.49x
P/S
—
Earnings and dividend metrics▾
Earnings
EPS
-$8.66
Earnings per share
BPS
$11.12
Book value per share
ROE
-77.9%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at $8.66 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $11.12 of net assets.
- ROE — shareholder equity shrank by 77.9% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue in the latest quarter: $198M.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
No year-ago figure was found for this quarter.
—
Jul–Sep '24
—
Jul–Sep '25
$198M
Jul–Sep '26
Blank bars mark quarters with no figure found in the filings.
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 4, 2026.
- Earnings per share decreased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Revenue has no year-ago figure on record, so no comparison is made.
- Operating income decreased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Net income decreased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
Filed Nov 4, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Anders JackChief Financial Officer · Nov 11, 2026Open-market sale35,750 shares · $6.7MAvg. price $188.1032
Show 11 price lots
- 9,889 shares × $192.8406$1.9M
- 9,486 shares × $191.9401$1.8M
- 5,776 shares × $182.0901$1.1M
- 3,499 shares × $181.0421$633K
- 2,700 shares × $182.8704$494K
- 1,900 shares × $184.0246$350K
- 800 shares × $185.0363$148K
- 600 shares × $187.3371$112K
- 500 shares × $190.994$95K
- 400 shares × $186.4138$75K
- 200 shares × $189.17$38K
- Anders JackChief Financial Officer · Nov 11, 2026Option exercise35,750 shares · $1.0MAvg. price $29.1852
Show 2 price lots
- 15,900 shares × $42.45$675K
- 19,850 shares × $18.56$368K
- Borisy AlexisDirector · Nov 11, 2026Gift10,625 shares · $0Avg. price $02,329,450 shares held after
- Mancini AnthonySee Remarks · Nov 9, 2026Open-market sale811 shares · $162KAvg. price $20039,765 shares held after
- Mancini AnthonySee Remarks · Nov 9, 2026Option exercise811 shares · $27KAvg. price $33.7043
Show 2 price lots
- 810 shares × $33.62$27K
- 1 shares × $102.02$102
- Mancini AnthonySee Remarks · Oct 26, 2026Open-market sale2,310 shares · $432KAvg. price $186.9939,765 shares held after
- Mancini AnthonySee Remarks · Oct 26, 2026Option exercise2,310 shares · $78KAvg. price $33.6242,075 shares held after
- Sandler Alan B.Chief Development Officer · Sep 29, 2026Open-market sale6,309 shares · $1.3MAvg. price $202.1389
Show 5 price lots
- 2,200 shares × $200.8188$442K
- 1,609 shares × $201.7239$325K
- 1,199 shares × $203.9074$244K
- 1,000 shares × $202.8127$203K
- 301 shares × $204.7224$62K
- Sandler Alan B.Chief Development Officer · Sep 29, 2026Option exercise6,000 shares · $353KAvg. price $58.8458,868 shares held after
- Mancini AnthonySee Remarks · Sep 25, 2026Open-market sale3,121 shares · $626KAvg. price $200.5439,765 shares held after
- Cislini JeffSVP & General Counsel · Sep 25, 2026Open-market sale765 shares · $159KAvg. price $207.320151,776 shares held after
- Mancini AnthonySee Remarks · Sep 25, 2026Option exercise3,121 shares · $105KAvg. price $33.6242,886 shares held after
- Mancini AnthonySee Remarks · Sep 24, 2026Open-market sale587 shares · $117KAvg. price $20039,765 shares held after
- ANDERSON ELIZABETH MDirector · Sep 22, 2026Open-market sale10,143 shares · $2.0MAvg. price $193.0411
Show 5 price lots
- 4,985 shares × $192.5387$960K
- 2,648 shares × $193.4392$512K
- 1,500 shares × $194.5887$292K
- 910 shares × $191.8521$175K
- 100 shares × $195.15$20K
- ANDERSON ELIZABETH MDirector · Sep 22, 2026Option exercise5,070 shares · $6KAvg. price $1.1214,476 shares held after
- Mancini AnthonySee Remarks · Sep 18, 2026Open-market sale1,764 shares · $347KAvg. price $196.9440,352 shares held after
- GOLDSMITH MARK ASee Remarks · Sep 16, 2026Open-market sale13,775 shares · $2.7MAvg. price $199.3032253,342 shares held after
- Kelsey Stephen MichaelSee Remarks · Sep 16, 2026Open-market sale5,484 shares · $1.1MAvg. price $199.3032286,307 shares held after
- Horn Margaret AChief Operating Officer · Sep 16, 2026Open-market sale4,891 shares · $975KAvg. price $199.3032149,680 shares held after
- Anders JackChief Financial Officer · Sep 16, 2026Open-market sale3,992 shares · $796KAvg. price $199.3032119,216 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Revolution Medicines (RVMD) stock information
NASDAQ
Revolution Medicines (RVMD) is listed on NASDAQ. Its market capitalization is about $37.2B. On trailing-twelve-month earnings the P/E ratio is -19.9, and the P/B ratio is 15.49. Return on equity is -77.9%. These figures are computed in-house from official filings and are reference information only.
Revolution Medicines — frequently asked questions
- What is the P/E ratio of Revolution Medicines (RVMD)?
- On a trailing-twelve-month basis, RVMD trades at a P/E ratio of -19.9. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Revolution Medicines?
- RVMD has a market capitalization of about $37.2B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.